In this context, effective reduction of tube formation and mitogenic activity of endothelial cells by ObR antagonist, especially in the combination with VEGFR2 inhibitor, suggest that targeting both leptin and VEGF pathways might represent a new therapeutic strategy to treat GBM. This evidence concerns the gene LEP and glioblastoma.